3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, B-Cell
5
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
4
Recurrence
3
Lymphoma, Mantle-Cell
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Lymphoma, B-Cell, Marginal Zone
2
Dendritic Cell Sarcoma, Interdigitating
2
Neoplasms
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
polatuzumab vedotin
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled